We’re pleased to announce the appointment of Pier Vincenzo Piazza as Aelis Farma’s new CEO.
Piervi’s appointment comes at a key moment in Aelis Farma’s development : the company is currently finalizing its phase 1 studies for AEF0117, its lead compound, and is actively preparing its phase IIa study in the field of cannabis addiction which will be conducted at Columbia University.
Piervi is an MD PhD also trained as a psychiatrist. He has been working full time on translational research since 1988. His particular field of expertise is the pathophysiology of behavior and in particular addiction, which he has been studying for 25 years.
Since 2007 and until his appointment as full time CEO of Aelis Farma, he was the director of the Neurocentre Magendie (INSERM, U862) in Bordeaux. The role of pregnenolone as a signaling specific allosteric inhibitor of the CB1 has been discovered by his research group. He cofounded Aelis Farma and has been acting as the director of its R&D activities until his appointment as CEO.
Previous to Aelis Farma, he cofounded two other biotech companies (Fluofarma and Alienor Farma), the former specialized in High Content Screening and the latter in the development of an anticancer drug. These two previous companies have given him a solid background in entrepreneurship and drug development.